Arch Biopartners Reaches Key Milestone in Cardiac Surgery Kidney Injury Trial

Arch Biopartners Inc., a late-stage clinical trial company, has reached a significant milestone.
The first patient has completed dosing at Toronto General Hospital (TGH), part of Canada’s largest academic health sciences centre.

The patient finished a five-day dosing schedule in the company’s Phase II trial.
This trial is testing LSALT peptide for preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI).

Why Toronto General Hospital Matters

• Global reputation – Ranked #3 in the world and Canada’s #1 hospital by Newsweek (2025 list).
• First Ontario site – The first clinical site in Ontario to dose a patient in this trial.
• Second in Canada – Joins University of Calgary Hospital as the second Canadian site.

More Sites Joining Soon

Arch expects St. Michael’s Hospital (Toronto) to be the next Canadian site, pending approvals.

The team is also working to open more sites across Canada and the United States. In Turkey, patient recruitment is being capped to diversify trial demographics.

CEO’s Take

“Dosing at Toronto General Hospital marks a key step forward,” said Richard Muruve, CEO of Arch Biopartners.
“We aim to recruit about half the patients in North America. Data from Turkey shows LSALT peptide has a strong safety profile.”

Inside the Phase II CS-AKI Trial

• Type – International, multi-centre, randomized, double-blind, placebo-controlled.
• Target – 240 patients.
• Treatment – LSALT peptide 10 mg IV twice daily for five days, or placebo.
• Goal – Measure acute kidney injury rates within seven days post–on-pump cardiac surgery (KDIGO criteria).

The Bigger Picture

CS-AKI often follows ischemia-reperfusion injury (IRI) — reduced blood flow to the kidneys followed by damaging inflammation.
No approved treatments currently prevent this complication.

In severe cases, AKI leads to kidney failure, dialysis, or the need for a transplant.

How LSALT Peptide Works

• Target – Blocks the DPEP1 enzyme, a driver of kidney inflammation.
• Evidence – Prevented IRI in pre-clinical models.
• Publications – Described in Cell (2019) and Science Advances (2022).

Earlier Phase II lung inflammation trials showed reduced inflammatory biomarkers, including CXCL10. This supports further testing for kidney, lung, and liver inflammation injury.

The Unmet Need

Up to 30% of patients undergoing on-pump cardiac surgery develop CS-AKI.
It raises the risk of serious complications, longer hospital stays, and higher mortality.

LSALT peptide could become a first-in-class therapy for this high-risk group.

About Arch Biopartners

Arch Biopartners develops novel drugs targeting the DPEP1 inflammation pathway in the kidneys, lungs, and liver.
The company focuses on preventing acute kidney injury and inflammation-driven organ damage.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!